Biontech and Pfizer produce Omikron-adapted vaccine


The Mainz-based pharmaceutical company Biontech and its US partner Pfizer have started production of a corona vaccine adapted to the Omikron variant for later commercial use.

This was announced by Biontech boss Ugur Sahin at a health conference of the US bank JP Morgan. A clinical study on the vaccine will begin at the end of January. “We assume that we will be ready for a supply to the market by March, if the regulatory approvals are available.” The European Medicines Agency (EMA) has not yet stated whether they want a vaccine adapted to Omikron with a different composition considers the vaccine currently in use to be necessary.

Biontech and Pfizer: 4 billion doses in 2022

For the year 2022, Biontech and Pfizer expect a production capacity of up to four billion vaccine doses worldwide. “We expect that there will also be strong demand for our vaccine in 2022,” said Sahin in his online presence.

A first comparison of the vaccination data with the population register is planned in Austria in the draft law on March 15th. Should it emerge from the comments in the assessment process that a change in the deadline is required for technical reasons, this will “of course be taken into account”. However, this does not change anything in the entry into force of the mandatory imprint in February. From this point in time, compliance with the obligation to vaccinate should also be widely monitored within the framework of official controls. (APA / red)

The current Covid-19 tracker can be found here!

The most important links from authorities and institutions for companies related to the coronavirus can be found here.


Share on facebook
Share on twitter
Share on linkedin

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

On Key

Related Posts